# Thymosin Alpha-1 Injection: How It Is Given in Studies

> Thymosin Alpha-1 injection as studied — the subcutaneous route used across the trials, the regimens by population, the pharmacokinetics, and the reported local reactions. No dosing guidance.

A subcutaneous peptide, reported as administered in the trials — route, rhythm, and the local reactions that follow.

## In plain English

In essentially every study, Thymosin Alpha-1 injection means one thing: a small shot of the peptide given under the skin — a subcutaneous injection, the same shallow kind used for insulin. It is not given as a pill (the peptide would be broken apart by digestion) and not, in the clinical record, through a vein. The peptide comes as a freeze-dried (lyophilized) powder that has to be mixed with sterile liquid before use. Because the body clears it from the blood within a day, trials gave it on a repeating schedule rather than once. The most-studied long-term schedule is a small twice-weekly shot; sepsis trials gave it more often for about a week. The most common thing people notice from the injection itself is a little redness or stinging at the spot. Everything below reports how the shot was used in research — not how anyone should use it.

## Why subcutaneous, and why repeated

The subcutaneous route is the clinical route for this peptide in essentially all trials [4]. The reason is partly the molecule: a short, highly acidic peptide cleared by aminopeptidases would not survive oral digestion, and its roughly 2-hour plasma half-life means a single dose clears within about a day [8]. Yet the immunological effect outlasts that brief plasma window, which is why intermittent injection works — the schedule chases the biology, not the blood level. Subcutaneous delivery also routes the peptide efficiently to immune tissue: a mouse biodistribution study found high uptake in thymus, spleen, and lungs after dosing [10].

## The injection regimens, by population

Reported as study-attributed research data — amounts given to defined populations by the subcutaneous route, not instructions:

- **Chronic hepatitis B/C** — `1.6 mg subcutaneous twice weekly`, the standard chronic regimen [9].
- **Sepsis (ETASS, TESTS)** — `1.6 mg subcutaneous every 12 hours for five to seven days` in adult ICU patients [2][3].
- **Severe COVID-19 cohorts** — `1.6 mg subcutaneous daily` [6].
- **Reported range** — single subcutaneous doses of `0.8-6.4 mg`; multiple-dose regimens `1.6-16 mg` over five to seven days [4].

Each figure belongs to its studied population; none generalizes to unstudied or self-directed use.

## What follows the injection

The injection is generally well tolerated. Across large post-marketing surveillance of hundreds of thousands of treated patients, the dominant adverse events were mild local reactions — redness, itching, burning, or discomfort at the injection site — with occasional transient flu-like symptoms and no documented organ toxicity at studied doses [15]. The [Thymosin Alpha-1 side effects](/side-effects) page covers the full reported safety picture; the short version is that the needle, not the molecule, accounts for most of what people report.

---

A standing record of what the thymus's quiet peptide has been measured to do — read from the literature, not whispered from a clinic, and nothing here is dispensed, prescribed, or sold.